Immutep Limited

NASDAQ:IMMP

Biotechnology

Healthcare
$0.37 +0.64%

+$0.00 today

Market cap
$55.01M
Beta
2.24
P/E (TTM)
-0.9
EPS (TTM)
-$0.06
52W Low $0.29High $3.53

Volume 3.10M

Average 13.46M

IMMP Research & Development

Spending on developing new products, technologies, and improvements to existing offerings.

Immutep LimitedNASDAQ: IMMP

Research & Development · Q2 FY2026 · quarter ended Dec 2025

Research & development remains negative

Q2 FY2026 research & development was A$0, compared with A$25.33M a year earlier. Over 3 fiscal years it compounded at +25.1% a year.

Context

  • Research & development amounted to 1217.6% of revenue in FY2025, up 136.1 pp from a year earlier.
  • Research & development increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterDec 2025
A$0— QoQ
Last fiscal yearJun 2025
A$61.41M+47.8% YoY
Research & Development past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-100.0%——
1 year+47.8%——
3-year CAGR+25.1%——
5-year CAGR——
10-year CAGR——

Research & Development history

AUD · from the income statement

Latest · FY2025
61.41M AUD
Year-over-year change
+47.8%
4-year CAGR
+37.4%

Research & Development vs competitors

How IMMP compares with its peers on the latest reported figures

  • Peers report in different currencies, so research & development is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +47.8% is the 3rd highest of 11, against a peer median of +11.9%.
  • Research & development amounts to 1217.6% of revenue for IMMP, versus a peer median of 329.9%.
IMMP Competitors
Research & Development for IMMP and competitors
Company Period LTM YoY 3-year CAGR% of revenue
CABACabaletta Bio, Inc.LTM Mar 2026$151.01M USD+44.8%+53.7%—
TRDAEntrada Therapeutics, Inc.LTM Mar 2026$143.25M USD+11.2%+28.8%2496.5%
ALLOAllogene Therapeutics, Inc.LTM Mar 2026$129.09M USD-32.1%-16.3%—
VNDAVanda Pharmaceuticals Inc.LTM Mar 2026$101.99M USD+14.6%+8.4%46.8%
CAPRCapricor Therapeutics, Inc.LTM Mar 2026$92.92M USD+60.8%+57.0%—
EDITEditas Medicine, Inc.LTM Mar 2026$66.19M USD-62.3%-19.9%171.1%
IMMPImmutep LimitedFY2025A$61.41M AUD+47.8%+25.1%1217.6%
PRQRProQR Therapeutics N.V.LTM Mar 2026€44.34M EUR+12.6%-7.1%329.9%
CADLCandel Therapeutics, Inc.LTM Mar 2026$36.32M USD+88.9%+13.6%—
ACHVAchieve Life Sciences, Inc.LTM Mar 2026$19.19M USD-29.2%-8.6%—
MREOMereo BioPharma Group plcLTM Mar 2026$18.13M USD-12.8%-16.7%3625.8%
Peer median (excluding IMMP) —+11.9%+0.6%329.9%

Competitors are the stored peer set for IMMP. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

AUD
Metric
FY2021
Jun 2021
FY2022
Jun 2022
FY2023
Jun 2023
FY2024
Jun 2024
FY2025
Jun 2025
Revenue3.86M170.37K3.51M3.84M5.04M
Cost of Revenue17.24M2.06M2.06M41.55M61.41M
Gross Profit(13.37M)(1.89M)1.44M(37.7M)(56.37M)
Gross Margin-346.2%-1111.2%41.2%-981.4%-1117.6%
Research & Development17.24M31.34M28.79M41.55M61.41M
Selling, General & Admin6.28M7.21M14.08M8.85M8.64M
Operating Expenses18.3M32.55M44.94M50.4M70.06M
Depreciation & Amortization1.89M1.84M1.86M2.01M2.13M
EBITDA(17.77M)(31.87M)(39.57M)(44.54M)(62.88M)
EBITDA Margin-460.0%-18708.9%-1128.8%-1159.4%-1246.6%
Operating Income(31.68M)(33.94M)(77.69M)(88.1M)(126.42M)
Operating Margin-820.0%-19920.0%-2216.0%-2293.3%-2506.5%
Interest Income105.33K224.52K939K3.88M5.25M
Interest Expense9.83K92.43K20.4K30.59K24.01K
Other Income / Expenses1.77M1.63M37.79M45.39M64.99M
Income Before Tax(29.9M)(32.21M)(39.9M)(42.72M)(61.43M)
Pre-Tax Margin-774.1%-18906.5%-1138.0%-1111.9%-1218.0%
Income Tax Expense3334000
Net Income(29.9M)(32.21M)(39.9M)(42.72M)(61.43M)
Net Margin-774.1%-18906.5%-1138.0%-1111.9%-1218.0%
EPS (Basic)(0.49)(0.37)(0.44)(0.36)(0.42)
EPS (Diluted)(0.49)(0.37)(0.44)(0.36)(0.42)
Weighted Avg Shares60.43M86.23M90.06M119.99M145.58M
Weighted Avg Shares (Diluted)60.43M86.23M90.06M120.11M145.58M

Immutep Limited

NASDAQ:IMMP

Intrinsic Alpha fair value

Locked

Current Price

$0.37

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.